Secretory leukoprotease inhibitor: A native antimicrobial protein presenting a new therapeutic option?

Thorax

Volumn 53, Issue 2, 1998, Pages 114-116

  Tomee, J F C ^a   Koeter G H ^a   Hiemstra, P S ^b   Kauffman, H F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti microbial activity; Secretory leukoprotease inhibitor

Indexed keywords

SERINE PROTEINASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; ENZYME INHIBITION; HUMAN; IMMUNOMODULATION; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN DETERMINATION; RESPIRATORY TRACT MUCOSA;

EID: 0031947103     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.53.2.114     Document Type: Article

References (13)

1. 1-proteinase inhibitor to combat pulmonary inflammation. Thorax 1996;51:1273-4.
2. Dijkman JH, Kramps JA, Franken C. Antileukoprotease in sputum during bronchial infections. Chest 1986;89:731-6.
3. Jin F, Nathan C, Radzioch D, Ding A. Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 1997;88:417-26.
4. Rudolphus A, Stolk J, Dijkman JH, Kramps JA. Inhibition of lipopolysaccharide-induced pulmonary emphysema by intratracheally instilled recombinant secretory leukocyte proteinase inhibitor. Am Rev Respir Dis 1993;147:442-7.
5. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995;96:456-64.
6. Turpin JA, Schaeffer CA, Bu M, et al. Human immunodeficiency virus type-1 (HIV-1) replication is unaffected by human secretory leukoprotease inhibitor. Antiviral Res 1996;29:269-77.
7. Hiemstra PS, Maassen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ, Dijkman JH. Antibacterial activity of antileukoprotease. Infect Immun 1996;64:4520-4.
8. Miller KW, Evans RJ, Eisenberg SP, Thompson RC. Secretory leukocyte protease inhibitor binding to mRNA and DNA as a possible cause of toxicity to Escherichia coli. J Bacteriol 1989;171:2166-72.
9. Tomee JFC, Hiemstra PS, Heinzel-Wieland R, Kauffman HF. Antileukoprotease; an endogenous protein in the innate mucosal defense against fungi. J Infect Dis 1997;176:740-7.
10. Tomee JFC, Wierenga ATJ, Hiemstra PS, Kauffman HF. Proteases from Aspergillus induce release of pro-inflammatory cytokines and cell detachment in airway epithelial cell lines. J Infect Dis 1997;176:300-3.
11. McElvaney NG, Nakamura H, Birrer P, et al. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerolization of recombinant secretory leukoprotease inhibitor. J Clin Invest 1992;90:1296-301.
12. McElvaney NG, Doujaiji B, Moan MJ, Burnham MR, Wu MC, Crystal RG. Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am Rev Respir Dis 1993;148:1056-60.
13. Sponer M, Nick H-P, Schnebli H-P. Different susceptibility of elastase inhibitors to inactivation by proteinases from Staphylococcus aureus and Pseudomonas aeruginosa. Biol Chem Hoppe-Seyler 1991;372:463-70.